Link to Full Article Acrux (ACR) is pushing ahead with its planned share purchase plan (SPP) by sending off a booklet to eligible shareholders. The pharmaceutical company first flagged plans to carry out a fundraise back in late-December, when it successfully netted $7.8 million via a placement. ACR is now hoping to raise an additional $2 […]
Link to Full Article Artarmon, Australia – December 22, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) announced today that the UK’s National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled “Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain.” The MIB states Evoke would be used as a […]
Link to Full Article Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-22 03:31:072021-01-05 03:33:15Destiny Pharma Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections
Link to Full Article LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating AuxoraTM in patients with severe COVID-19 pneumonia has received a recommendation to continue, following a […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-17 03:28:182021-01-05 03:29:24CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
Link to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-17 03:23:262021-01-05 03:26:20ARECOR’S PARTNER INHIBRX EXERCISES ITS OPTION TO LICENSE A NEW FORMULATION DEVELOPED BY ARECOR IN ACCORDANCE WITH THE TERMS OF FORMULATION DEVELOPMENT AGREEMENT
Link to Full Article AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-16 02:38:062020-12-17 02:44:27ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT247 IN DIABETES CARE
Link to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-14 02:33:002020-12-17 02:37:46ARECOR FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF ULTRA-CONCENTRATED RAPID ACTING INSULIN CANDIDATE, AT278, FOR DIABETES
Link to Full Article Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robin C. Kramer was elected by the Armata shareholders […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-09 02:44:522020-12-17 02:46:09Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
Melbourne, Australia 9 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd is thrilled and honoured to receive the Michael Hirshorn Award for 2020, as part of the Australian Investment Council Investing for Growth Awards 2020. Instituted in 2012, and named in honour of the late Michael Hirshorn, co-founder and CEO of Cochlear, the […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2020-12-09 00:36:412020-12-10 00:37:58BioScience Managers Proud to Receive Prestigious Michael Hirshorn Award
Link to Full Article GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM […]
Acrux (ASX:ACR) pushes ahead with $2M SPP
/in AcruxLink to Full Article Acrux (ACR) is pushing ahead with its planned share purchase plan (SPP) by sending off a booklet to eligible shareholders. The pharmaceutical company first flagged plans to carry out a fundraise back in late-December, when it successfully netted $7.8 million via a placement. ACR is now hoping to raise an additional $2 […]
NICE Publishes Briefing on Saluda’s Evoke Closed-Loop Spinal Cord Stimulation (SCS) System
/in Saluda MedicalLink to Full Article Artarmon, Australia – December 22, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) announced today that the UK’s National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled “Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain.” The MIB states Evoke would be used as a […]
Destiny Pharma Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections
/in Destiny PharmaLink to Full Article Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the […]
CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia
/in CalcimedicaLink to Full Article LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating AuxoraTM in patients with severe COVID-19 pneumonia has received a recommendation to continue, following a […]
ARECOR’S PARTNER INHIBRX EXERCISES ITS OPTION TO LICENSE A NEW FORMULATION DEVELOPED BY ARECOR IN ACCORDANCE WITH THE TERMS OF FORMULATION DEVELOPMENT AGREEMENT
/in ArecorLink to Full Article ARESTAT™ formulated product progressing into clinical trial Cambridge, UK., 17th December 2020: Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, […]
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT247 IN DIABETES CARE
/in ArecorLink to Full Article AT247, a promising candidate in the pursuit for next generation insulins to improve glycemic control Cambridge, UK, 16 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of […]
ARECOR FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF ULTRA-CONCENTRATED RAPID ACTING INSULIN CANDIDATE, AT278, FOR DIABETES
/in ArecorLink to Full Article Development of a rapid acting concentrated insulin for advanced delivery systems and enabling fewer injections for high dose diabetics Cambridge, UK., 14 December 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives announces dosing of the first patient in a Phase I clinical […]
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
/in Armata PharmaceuticalsLink to Full Article Biogen Chief Accounting Officer adds significant financial leadership experience MARINA DEL REY, Calif., Dec. 9, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robin C. Kramer was elected by the Armata shareholders […]
BioScience Managers Proud to Receive Prestigious Michael Hirshorn Award
/in BioSciences ManagersMelbourne, Australia 9 December 2020: Leading Australian-based healthcare investment firm BioScience Managers Pty Ltd is thrilled and honoured to receive the Michael Hirshorn Award for 2020, as part of the Australian Investment Council Investing for Growth Awards 2020. Instituted in 2012, and named in honour of the late Michael Hirshorn, co-founder and CEO of Cochlear, the […]
GEN INCODE APPOINTS CHIEF FINANCIAL OFFICER
/in GenInCodeLink to Full Article GEN inCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease announces today the appointment of Paul Foulger as Chief Financial Officer to the Company. Paul Foulger is an experienced CFO with a proven, demonstrable track record in the Biotech industry for both AIM […]